Key result
Qiliqiangxin Capsule alleviated Angiotensin II-stimulated cardiac hypertrophy and cardiac dysfunction in mice and cardiomyocytes via the miR-382-5p/ATF3 axis.
Why the study?
The study investigated the possible role of Qiliqiangxin Capsule in cardiac hypertrophy.
Does Qiliqiangxin Capsule alleviate Angiotensin II-induced cardiac hypertrophy and dysfunction in mice and cardiomyocytes?
Population
Neonatal mouse ventricular cardiomyocytes and mice with Ang-II-induced cardiac hypertrophy
Comparison
Qiliqiangxin capsule vs control or Ang-II alone
Design
In vitro and in vivo preclinical study
Authors
Loading...
Hypothesis-generating for QL in Ang-II hypertrophy; human trials needed before clinical consideration.
Does Qiliqiangxin Capsule alleviate Angiotensin II-induced cardiac hypertrophy and dysfunction in mice and cardiomyocytes?
Qiliqiangxin Capsule alleviates Angiotensin II-induced cardiac hypertrophy and dysfunction in preclinical models by regulating the miR-382-5p/ATF3 axis.
Bao et al. (2024) studied Cardiac hypertrophy. Qiliqiangxin Capsule (QL) vs. Angiotensin II alone was evaluated on Cardiac hypertrophy and cardiac dysfunction. Qiliqiangxin Capsule alleviated Angiotensin II-stimulated cardiac hypertrophy and cardiac dysfunction in mice and cardiomyocytes via the miR-382-5p/ATF3 axis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: